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Abstract
The angiogenic process is controlled by variety of factors of which the vascular endothelial growth factor (VEGF) pathway
plays a major role. A series of heparan sulfate mimetic small molecules targeting VEGF/VEGFR pathway has been
synthesized. Among them, compound 8 (2-butyl-5-chloro-3-(4-nitro-benzyl)-3H-imidazole-4-carbaldehyde) was identified as
a significant binding molecule for the heparin-binding domain of VEGF, determined by high-throughput-surface plasmon
resonance assay. The data predicted strong binding of compound 8 with VEGF which may prevent the binding of VEGF to
its receptor. We compared the structure of compound 8 with heparan sulfate (HS), which have in common the functional
ionic groups such as sulfate, nitro and carbaldehyde that can be located in similar positions of the disaccharide structure of
HS. Molecular docking studies predicted that compound 8 binds at the heparin binding domain of VEGF through strong
hydrogen bonding with Lys-30 and Gln-20 amino acid residues, and consistent with the prediction, compound 8 inhibited
binding of VEGF to immobilized heparin. In vitro studies showed that compound 8 inhibits the VEGF-induced proliferation
migration and tube formation of mouse vascular endothelial cells, and finally the invasion of a murine osteosarcoma cell line
(LM8G7) which secrets high levels of VEGF. In vivo, these effects produce significant decrease of tumor burden in an
experimental model of liver metastasis. Collectively, these data indicate that compound 8 may prevent tumor growth
through a direct effect on tumor cell proliferation and by inhibition of endothelial cell migration and angiogenesis mediated
by VEGF. In conclusion, compound 8 may normalize the tumor vasculature and microenvironment in tumors probably by
inhibiting the binding of VEGF to its receptor.
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Introduction
There is a need for anticancer agents with novel mechanisms of
action [1]. Recently identified molecular targets for new antican-
cer agents include, inducers of cell differentiation, cell cycle arrest,
and apoptosis, as well as inhibitors of mitogenic signaling pathways
elicited by growth factors and cytokines [2,3,4]. A largely
unexplored opportunity is the use of carbohydrate mimetics as
drugs [5]. The development of new synthetic methods for sugar
mimetics has led to a wide variety of novel structures, such as
oxazines, triazole-imines, isoxazolines, and imidazole derivatives
[6,7,8] that may exert anti-tumor activity. The cell surface and
extracellular matrix heparan sulfate (HS) is known to play a major
role in tumor metastasis, and acts as a storage site for various
proteins [9]. Heparan sulfate glycosaminoglycans (HSGAGs) have
been found to play regulatory roles in many biological functions;
both normal physiological processes (e.g., embryogenesis) as well
as pathological processes (e.g., tumorigenesis and metastasis).
The approach of modulating tumor progression with drugs that
inhibit growth of tumors/endothelial cells or the activities of
angiostatic factors represents a new concept in adjuvant chemo-
therapy when used alone or in combination with classic antitumor
drugs. This approach is being explored either with the use of
monoclonal antibodies directed to the factors [10] or with growth
factor-complexing molecules of different origin such as suramin
[11], polysaccharide [12], and anionic compounds [13]. The
sulphonated derivative of distamycin A, FCE 26644, has been
found to inhibit angiogenesis and showed anti-tumor activity by
complexing with the growth factors [14,15]. Most recently, a
VEGF-A receptor neuropilin 1 binding ligand (EG00229) was
designed and synthesized that reduced the viability of A549 lung
carcinoma cells [16]. The proliferation and growth of solid tumors
in vivo is dependent on various growth factors and cytokines, either
through a direct stimulus to cell division and/or through activation
of neovascularization, an essential event in tumor progression and
metastasis [17]. The increased production of vascular endothelial
growth factor (VEGF), fibroblast growth factor-2 (FGF-2),
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heparin-binding epidermal growth factor-like growth factor (HB-
EGF), and tumor necrosis factor-a (TNF-a), as well as the
overexpression of their receptors has been reported in a variety of
human tumors [17]. It is well known that both VEGF and FGF-2
are capable of stimulating angiogenesis in vitro and in vivo [18].
During angiogenesis, the proliferation, migration and remodelling
of fully differentiated endothelial cells to form microvessels are
regulated by growth factors such as VEGF or FGF secreted by
tumor cells [19]. Therefore, the inhibition of VEGF or FGF
expression or blocking their mitogenic response on endothelial
cells might have therapeutic value in the treatment of a variety of
cancers [20].
The enormous structural diversity of HSGAGs makes it possible
for them to interact specifically with a wide variety of proteins and
other ligands. Synthesis of such HS mimetic compounds with
antitumor and antiangiogenic properties are currently an active
area of research. In order to dissect a variety of the pathological
roles of HSGAGs and specifically to identify and develop novel
anti-tumor agents, we explored virtual libraries of HSGAG-
mimetic compounds using database search techniques. The
literature revealed the anti-tumor and anti-heparanase activities
of a non-sugar-based HS mimetic compound 2-[3-nitro-4-
(phenylthio)benzoyl]benzoic acid (KI-105) [21]. We herein,
synthesized these types of compounds, which bear HS mimetic
structure in order to evaluate their efficacy in preventing the
invasion and proliferation of tumor cells. Here, we prepared the
hybrid of HS-mimetic core structure of KI-105 by replacing the
benzene group by imidazole, since the chemistry of imidazole
occupies an extremely important niche within the family of 5-
membered heterocyclic compounds. 2-butyl-5-chloro-3-(4-nitro-
benzyl)-3H-imidazole-4-carbaldehyde (compound 8) is consid-
ered to mimic the HS non-structurally. We report that the
compound 8, directly binds to the heparin binding domain of
VEGF, as detected by high throughput surface plasmon resonance
(SPR) analysis, as well as by in silico binding analysis, and showed
promising antitumor activity in experimental model of liver
matastasis.
Results and Discussion
Several studies have shown that HS mimetics act as antitumor
agents [21]. However, the pleiotropic effects and interactions of
such mimetics with heparin-binding proteins might elicit off-target
effects associated with toxicity. Low molecular weight HS
mimetics which perform multiple biological functions in vivo and
in vitro with high specificity are rare. To this end, we sought to
synthesize a series of novel non-sugar-based compounds which can
mimic the HS non-structurally.
Synthesis
Synthesis of small molecules (1–9) is shown in Figure 1, which
depicts the synthesis of 1,3-oxazine derivatives, 1,2,4-triazole
derivatives, and imidazole derivatives. 1,3-oxazine derivatives 1–4,
were prepared by the cyclization of 1-[2-amino-1-(4-methoxy-
phenyl)-ethyl]-cyclohexanol monoacetate with aromatic or ali-
phatic aldehydes in the presence of potassium carbonate [22,23].
4-Amino-4,5-disubstituted-[1,2,4] triazole-3-thiols 5–7, were syn-
thesized by condensation reaction of 4-amino-5-methy/ethyl/
phenyl-4H-[1,2,4]triazole-3-thiols with 1,6-difluorobenzaldehyde
in presence of catalytic amount of concentrated sulphuric acid in
ethanolic media (Figure 1). Microwave-assisted synthesis of N-
substituted 2-butyl-5-chloro-3H-imidazole-4-carbaldehyde deriva-
tives 8 and 9, were synthesized as reported [24,25].
High throughput surface plasmon resonance (SPR)
screening of small molecules binding to growth factors
We immobilized the HS-mimetic small molecule libraries
(around 60) in order to determine their binding ability with
heparin-binding growth factors such as VEGF, FGF-2, TNF-a,
midkine, pleotrophin, or HB-EGF by conducting a novel SPR
assay (Basappa et al, Cancer Letter, 2010; Supplementary Fig. 1–
3). An overview of the SPR analysis is shown in Figure 2A.
Compounds were immobilized on the photoaffinity-linker-coated
gold substrates (PGSs) as reported previously [26,27]. In our in vitro
experimental conditions, strong SPR signals for the direct binding
of the selected compounds (1–9) with VEGF (Figure 2B) or FGF-
2 (Figure 2C) were found. Compound 2 bound to VEGF
moderately when compared to other oxazine molecules tested
during the assay. Among the triazole compounds like 5, 6, and 7,
compound 6 bound to VEGF significantly. More importantly, the
imidazole derivative, compound 8, bound to VEGF very
strongly, when compared to other screened molecules by SPR
assay. It also interacted with FGF-2 significantly, although with
weaker affinity compared to its VEGF binding. Some of the
synthesized compounds weakly bound to other heparin-binding
growth factors such as HB-EGF or TNF-a (data not shown). In
addition, none of the compounds showed any binding to
pleiotrophin and midkine (data not shown). The assay was found
to be specific in terms of binding; hence these results indicate the
binding specificity of compound 8 towards VEGF and led us to
Figure 1. Reagents and condition: a) R1-CHO, K2CO3, Methanol, RT;
b) 2,6-difluorobenzaldehyde, Conc. H2SO4, ethanol, reflux; c) R1-Cl,
K2CO3, DMF, RT.
doi:10.1371/journal.pone.0039444.g001
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speculate that this molecule may be used to modulate the cellular
processes that are mediated by VEGF.
Molecular interaction of compound 8 with the heparin
binding site of VEGF165
We initially prepared the energy minimized structures of the
synthesized molecules. The results of the calculations were
compared those for HexUA-GlcNAc(6S). Finally, we selected
compound 8 as the core structure (Figure 3A). The energy-
minimized structures of HexUA(2S)-GlcNAc(6S) and compound
8 revealed that anionic groups, such as sulfate, carboxylic acid,
carbaldehyde and nitro functional groups, are able to locate in
similar positions and directions (Figure 3B). Because of structural
similarity (by functional groups) to HS, compound 8 could bind
to VEGF165 in the heparin binding site. Compound 8 interacts
with VEGF strongly, and FGF-2 weakly as determined by SPR
assay, hence we performed the molecular docking processes using
CDOCKER, which docks ligands to the heparin binding site of
VEGF (27). The molecular docking studies predicted that
compound 8 binds to the heparin binding domain of VEGF
(Figure 4A) with high binding affinity while some other
compounds do not show affinity towards the heparin binding site
of VEGF (data not shown). Compound 8 showed the
CDOCKER score (-CDOCKER ENERGY) of 24.7, a high
value, which indicates more favourable binding. This score
includes internal ligand strain energy and receptor-ligand interac-
tion energy, and is used to sort the different conformations of each
input ligand. Visual analysis of the docked compound 8 shows
the imidazole and benzene nucleus resides in the pocket formed by
Val-19, Phe-18, His-15, Lys-16, and Pro-9. In addition, the
compound 8 bound through hydrogen bonding with Lys-30 and
Gln-20 residues at the heparin binding pocket of VEGF
(Figure 4B). On the other hand, we found the hydrophobic
interaction of the butyl group of compound 8 with the heparin
binding domain of FGF-2 with a CDOCKER score of 4.8, which
is lower when compared to VEGF interaction CDOCKER score
(Fig. S1). This revealed that the binding of compound 8 with
VEGF is stronger when compared to FGF-2. A similar observation
has been reported previously for the compound KI-105 that
bound to the HS binding site of heparanase [21]. We know that
HS binds to heparin-binding growth factors and cytokines such as
VEGF and FGF-2. We analysed the interaction between VEGF165
and bound heparin using the BIAcore system. This study revealed
that compound 8 inhibited the binding of VEGF165 to the
immobilised heparin (Figure 4C). Although the concentration of
compound 8 needed to inhibit the binding of VEGF to the
heparin was high, these data show that the molecular interaction
takes place. In addition, the structurally related compound 7 that
does not bind VEGF, failed to inhibit the binding of VEGF to
heparin, suggesting selectivity. The results indicate that com-
pound 8 initially competes or is bound initially to the heparin
binding domain of VEGF and thereby decreases the binding of
VEGF to the immobilized heparin.
Effect of small molecules on the proliferation of tumor
cells
Small-molecules that intervene in biological systems have been
sought as tools to perturb signaling pathways and of course as
therapeutic agents for disease. Heparin and HS structural
mimetics have been reported as antitumor agents that significantly
inhibit tumor growth, metastasis, and angiogenesis. To validate
the binding ability of these compounds with VEGF and to further
elucidate the biological functions of these molecules, we initially
examined the effects of compounds 1–9 on the proliferation of
murine osteosarcoma cell lines, LM8 and LM8G7, which are
known to the secrete proangiogenic factor VEGF [28]. Com-
pounds 1–4, 6, 7, and 9 did not show promising inhibitory
activity towards the proliferation of osteosarcoma cancer cells
(Table 1). Compounds 5 and 6 inhibited moderately the
proliferation of LM8 and LM8G7 cells. In contrast to other
compounds, compound 8, which bears an imidazole moiety,
showed more potent inhibition towards the proliferation of VEGF-
secreting LM8 and LM8G7 cells with an IC50 values of 7 mM and
4.5 mM, respectively. In comparison cisplatin was less potent with
IC50 concentrations of 30 and 15 mM, respectively (Table 1). The
inhibitory activity of suramin was comparable with the inhibitory
activity of compound 8 on the proliferation of tumor cells.
Real-time monitoring of the effect of compound 8 on the
proliferation of LM8G7 cells
Elimination or arrest of tumor cell proliferation in the target
organ are the eventual objectives of anticancer therapy. We
monitored the effect of compound 8 (2 to 50 mM) on the
proliferation of VEGF secreting LM8G7 cells using real-time cell
electronic sensing systemTM (RT-CES) to confirm the results
obtained through TetraColor One assay. Compound 8 inhibited
the proliferation of LM8G7 cells in a concentration-dependent
manner with an IC50 value 5 mM, confirming its anti-proliferative
effect on LM8G7 cells (Figure 5A).
Effect of small molecules on the proliferation of
endothelial cells
The proliferation and migration of endothelial cells to form
microvessels is critical for angiogenesis, and inhibition of
angiogenic factor-mediated proliferation of endothelial cells has
been shown to be an effective antiangiogenic therapy [29]. Hence,
we tested the effects of these compounds on the VEGF-induced
Figure 2. Interaction between the small molecules and growth
factors. An overview of the SPR analysis showing the interaction
between the sugar mimetics and growth factors/cytokines (A). Small
molecules (1–9) were immobilized on the photoaffinity-linker-coated
gold substrates. Interactions were detected between the small
molecules (1–9) and the growth factors in solution by SPR imaging
as described under ‘‘Experimental Procedures’’. The maximum SPR
signal strength observed between the small molecules (1–9) and VEGF
(B), or FGF-2 (C) are presented.
doi:10.1371/journal.pone.0039444.g002
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proliferation of endothelial (UVR2) cells. Except for compounds 6,
the remaining compounds had no significant effects on the
proliferation of UVR2 cells, whereas compound 6 which had weak
binding with VEGF moderately inhibited its proliferation.
Figure 3. Discovery of New HS mimetic small molecule. Left.
Chemical structure of a HS disaccharide unit (1), HexUA(2S)-GlcNAc(6S),
and compound 8 are also shown. Right. Energy-minimized structures of
HS and compound 8. The arrows show the anionic functional groups.
The carbon, oxygen, nitrogen, and sulfur atoms are represented in green,
red, blue, and yellow, respectively. The hydrogen atoms are not shown.
doi:10.1371/journal.pone.0039444.g003
Figure 4. Molecular basis for the interaction between com-
pound 8 and heparin binding domain of VEGF165. A. Binding
mode of compound 8 with heparin binding site of VEGF165. The amino
acid residues of heparin binding site of VEGF165 are shown in stick
models. B. Interactions of the compound 8 within the heparin binding
pocket of VEGF165 with putative hydrogen bonds shown as green
dotted lines. The compound 8 is shown in green color. The bonding
between the compound 8 and the heparin binding domain of VEGF165
are shown in yellow color. All the hydrogen atoms are not shown. The
picture is rendered in Discovery Studio, version 2.5 (right panel). C.
Binding of VEGF165 to immobilised-heparin. Various concentrations of
compound 8 and VEGF165 (250 nM) mixture in running buffer was
injected onto the surface of the heparin-immobilised sensor chip.
Sensograms obtained were overlaid using a BIA evaluation software
(version 3.1).
doi:10.1371/journal.pone.0039444.g004
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Compound 8, which strongly binds to VEGF, markedly
inhibited the proliferation of UVR2 cells with an IC50 value of
42 mM (Table 1). These results show that compound 8
suppressed the proliferation of endothelial cells, but the concen-
tration of compound 8 required to suppress cell proliferation was
high compared with that required to suppress proliferation of
LM8G7 osteosarcoma cells.
In contrast to UVR2 cells treated with compound 8 under
serum-containing conditions (10%FBS), compound 8 showed a
potent inhibitory effect on the VEGF-stimulated proliferation with
an IC50 value 0.3 mM (Figure 5B). These results indicate that
compound 8 inhibited endothelial cell proliferation through
inhibition of VEGF receptor function.
We next examined the effect of compound 8 to suppress
VEGF-stimulated proliferation of HUVECs. As shown in
Figure 5C, proliferation was inhibited approximately 40% at
1 mM, and by 50% at 10 mM. Taken together, these data suggest
that compound 8 can block the VEGF-mediated angiogenic
response in endothelial cells.
Compound 8 suppresses VEGF-induced migration and
tube formation of endothelial cells
Endothelial cell migration is critical events for angiogenesis. To
examine whether compound 8 inhibited migration of UVR2
endothelial cells the effect of compound 8 against the VEGF-
induced migration across the porous membrane of BD BioCoatTM
chambers was determined. VEGF significantly enhanced migra-
tory activity and cotreatment with compound 8 resulted in
significant inhibition of VEGF-induced migration. Cells were
treated with VEGF, drug vehicle (0.5% DMSO, Control) or
compound 8 at 0.5 and 1.0 mM. Representative photomicro-
graphs are shown in Figure 6A–C. Quantification of the
reduction in migration showed that compound 8 significantly
inhibited VEGF-induced migration of endothelial cells by 52, and
83%, at 0.5 and 1.0 mM, respectively (Figure 6D). Further,
compound 8 at 1 mM was non-toxic as is evident from the
TetraColor One assay (Table 1); hence, the inhibitory effect could
not be attributed to cytotoxic activity.
Stimulation of endothelial cells on ECMatrixTM by angiogenic
factors such as VEGF promotes differentiation to form capillary-
like tubes. We performed the tube formation assay to assess any
Table 1. Inhibition of the proliferation of tumor and
endothelial cells by compounds 1–9 (IC50 in mM).
Compound R1/R2/R3 LM8 LM8G7 UVR2
1 H NSa NS NS
2 4-Fluoro-phenyl 6460.5 8660.1 NS
3 4-Chloro-phenyl NS .100 NS
4 pyridin-3-yl 9566.7 NS .100
5 Methyl 3666.4 NS 4562.1
6 Ethyl 6466.7 2360.5 1464.6
7 Phenyl .100 NS NS
8 4-Nitro-phenyl 6.860.3 562.8 4260.1
9 6-methyl-benzo[1,3]
dioxol-5-yl methyl)-
4666.7 NS NS
Suramin 1262.8 14624 3461.4
Cisplatin 30624 1560.6 1260.4
aNS, not significant.
doi:10.1371/journal.pone.0039444.t001
Figure 5. A. Real-time monitoring of the effects of compound 8
on the proliferation of LM8G7 cells. Cells were seeded in ACEA’s
966 e-plateTM at a density of 56103 cells per well, and continuously
monitored using the RT-CES system up to 24 h, at which point
Compound 8 (2 to 50 mM) was added. The cell index is plotted against
time. The arrow indicates the time of the addition of compound 8. Data
represent the mean values 6 S.D. for three identical wells from three
independent experiments. B, compound 8 poorly inhibited prolifera-
tion of UVR2 under serum-replete conditions (FBS), but potently inhibited
VEGF-dependent proliferation of UVR2 cells as analysed by TetraColor
One assay. Results were normalised to DMSO controls. Data represent
mean values 6 SD for three independent experiments. * P,0.05 versus
control. ** P,0.01 versus control. C, compound 8 inhibits VEGF-
stimulated proliferation of human vascular endothelial cells. HUVEC cells
were seeded on 6-well plates at a density of approximately 16105 cells/
well in M200 medium supplement with LSGS (Low serum growth
Supplement). The next day cells were stimulated with 10 ng/mL of VEGF
in the presence or absence of 1 mM and 10 mM compound 8. After
48 hrs, Alamar Blue was added directly into culture media at a final
concentration of 10% and the plate was returned to the incubator.
Optical density (OD) of the plate was measured at 540 and 630 nm. As a
negative control, AB was added to medium without cells.
doi:10.1371/journal.pone.0039444.g005
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specific effect of compound 8 on this process. The results showed
that VEGF significantly increased tube formation (Figure 6E)
and cotreatment of endothelial cells with compound 8 at 0.5 to
1 mM resulted in strong inhibition of VEGF-induced tube
formation in a concentration-dependent manner (Figure 6F
and G). At 1 mM compound 8 resulted in complete inhibition of
the tube formation by the endothelial cells. The combined results
show that compound 8 suppressed the proliferation of endothe-
lial cells, but the concentration of compound 8 required to
suppress the proliferation was high compared with that required to
suppress the tube formation and cell migration. However, the
compound 8 failed to inhibit the FGF-2-induced tube formation
by the endothelial cells at the tested concentrations (Figure S2).
Taken together, we observed that compound 8 may block the
VEGF-mediated angiogenic response in endothelial cells.
Effect of compound 8 on the invasion of LM8G7 cells
The effect of compound 8 on the invasion of highly metastatic
LM8G7 cells across MatrigelTM-coated porous membranes was
studied. Control (DMSO-treated) LM8G7 cells were highly invasive
in the assay (Figure 7A). Compound 8 at 0.5 and 1 mM
(Figure 7B and C) effectively inhibited the invasion of LM8G7
cells by 46, and 75% (Figure 7D), respectively, when compared to
control. Compounds 1–7 and 9 failed to inhibit the invasion of
LM8G7 cells at 1 mM concentration effectively (data not shown).
Compound 8 prevents experimental liver metastasis
Because compound 8 potently inhibited endothelial cell
migration and tube formation, as well as LM8G7 cell proliferation,
we examined the in vivo anti-tumor effect of compound 8.
Following intravenous injection of LM8G7 cells mice developed
metastatic nodules in the liver within 30 days (Figure 8A). In
contrast, mice treated intravenously with compound 8 (0.5 or
1.0 mg/kg, days 3, 5, and 10) or heparin (5 mg/kg, used on the
same schedule of administraion as a positive control) were
completely free of metastatic nodules in the liver, Figure 8B
and C, respectively. Compound 8 at 0.25 mg/kg treatment,
failed to inhibit the tumor formation by the LM8G7 cells
(Figure 8D). The animals tolerated the dosages of compound
8 (0.5 to 1.0 mg/kg), with no signs of toxicity or weight loss during
the experiments (data not shown). Unlike heparin, compound 8
did not show anti-coagulant activity in vitro (data not shown). In
addition, heparin at 2.5 mg/kg dose failed to inhibit the metastasis
of LM8G7 cells (Figure 8D). We also evaluated the effect of
compound 8 (0.25 mg/kg) in combination with heparin
(2.5 mg/kg). As shown in Figure 8D, the combination treatment
resulted in complete abrogation of metastatic tumor nodules.
Summary
We demonstrated here that the compound 8 strongly
interacted with VEGF as evidenced by a novel SPR assay.
Molecular docking calculations revealed that hydrogen bonding
interactions may play crucial role in demonstrating biological
activity. Concerning the mechanism of action, we observed that
compound 8 may displace VEGF from its specific binding sites
on HUVECs. It is noteworthy that HS mimetic compound 8
might therefore behave as an antagonist or partial agonist. Since
heparin can interfere with VEGF action either by binding to a
specific domain on VEGF or by interacting with its cellular
binding sites, KDR or NRP1, Consequently, compound 8 might
affect both the ligand and its cellular binding sites. We show here
that compound 8 interacts directly with VEGF. This is in
agreement with our previous findings that compound v bound to
FGF2, and thus altering the conformation of ligand receptor
complexes. Compound 8 showed in vitro antiproliferative activity
against LM8G7 osteosarcoma cells (endogenously expressing
VEGF), and inhibited their invasiveness. Compound 8 inhibited
the VEGF induced endothelial tube formation by UVR2 cells and
suppressed VEGF-stimulated proliferation and tube formation of
HUVEC cells. In vivo, compound 8 potently inhibited formation
of liver metastases following intravenous injection of LM8G7
osteosarcoma cell. Collectively, these data indicate that com-
pound 8 may prevent tumor growth through a direct effect on
tumor cells by blocking VEGF paracrine or autocrine stimulated
proliferation and by inhibition of endothelial cell migration and
angiogenesis mediated by VEGF. In conclusion, the effects of
compound 8 are probably through inhibiting the binding of
VEGF to its receptor. Furthermore, to the best of our knowledge,
this is the first report on a non-structural HS mimetic, which
interacts directly with VEGF. Our data suggest that compound 8
has potential use to build a therapeutic drug for minimizing tumor
growth and angiogenesis in VEGF related models.
Materials and Methods
Cisplatin, recombinant human (rh)-FGF-2, and rh-VEGF165
were purchased from Wako Pure Chemicals Co. (Osaka, Japan).
1006 non-essential amino acids, b-mercaptoethanol, 1006
sodium pyruvate and L-glutamine were from GIBCO (Auckland,
New Zealand). The cell proliferation assay kit Tetracolor One was
Figure 6. Compound 8 suppresses VEGF-induced migration
and angiogenesis. UVR2 cells (2.56104) were seeded along with VEGF
(2 ng/ml) in Boyden-chambers and incubated for 24 h with DMEM (A)
or a medium containing 0.5 mM of compound 8 (B) or 1 mM
compound 8 (C); the photographs (1006) shows the cell on the
lower surface of the filter (migrated) stained with the Diff-Quick
solution. (D) Inhibition rate of the compound 8 on UVR2 migration
was presented as described under ‘‘Experimental Procedures’’. Data
represent the mean values 6 S.D. for three identical wells from three
independent experiments. Bars represent the mean 6 SD of three
independent experiments. * P,0.05 versus control. ** P,0.01 versus
control. The UVR2 cells were seeded in 6-well plates pre-coated with
MatrigelTM (ECM 625, Chemicon) was added to a 24-well plate in a final
volume of 100 mL and allowed to solidify at 37uC for 30 min. UVR2 cells
(46105 cells) were seeded to the ECMatrixTM-coated wells in the
presence or absence of compound 8 (0.5 (F) or 1 mM (G) along with
2 ng/ml VEGF. After 18 h of culture, the reorganization of the sub-
confluent monolayer of UVR2 cells in 3-dimensional MatrigelTM was
monitored and photographed under an Olympus FX380 microscope
attached to a 3CCD camera.
doi:10.1371/journal.pone.0039444.g006
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obtained from Seikagaku Corp. (Tokyo, Japan) and the Diff-Quick
solution was from International Reagent Corp. (Kobe, Japan). All
other chemicals and reagents used were of the highest commercial
grade available.
The melting points were determined on a SELACO-650 hot stage
apparatus and are uncorrected. IR (KBr) spectra were recorded on a
Jasco FT/IR-4100 Fourier transform infrared spectrometer, 1H
NMR were recorded on a Shimadzu AMX 400 spectrometer using
CDCl3 as solvent and TMS as an internal standard (chemical shift in
ppm). Elemental analyses were obtained on a vario-EL instrument
and were within 60.4% of calculated values. Thin layer chroma-
tography (TLC) was conducted on 0.25 mm silica gel plates (60F254,
Merck). Visualization was made with ultraviolet light. All extracted
solvents were dried over anhydrous Na2SO4 and evaporated with a
BUCHI rotary evaporator. Silica gel (200–400 mesh) from Aldrich,
Inc., was used for column chromatography. All other chemicals were
obtained from Aldrich, Inc.
Preparation of the compounds 1–4, 8, and 9
Compounds 1, 8, and 9 were prepared by the methods
described in our previous papers [25,30].
The compounds 5 to 7 were prepared by the following
procedure
Equimolar amount of 4-amino-5-substituted-4H-[1,2,4]triazole-
3-thiols and 2,6-difluoro-benzaldehyde were heated in ethanol
(10 ml) until a clear solution was obtained. Then a few drops of
conc. H2SO4 were added and the solution was refluxed for 3–4 h
on a water bath. After completion of the reaction, the solvent was
evaporated, water was added, and cooled to 10–15uC. The
product was filtered at the same temperature, and the residue
washed with chilled n-hexane, dried and recrystallised with ethyl
acetate to obtain the pure compounds.
4-[(2,6-Difluoro-benzylidene)-amino]-5-methyl-4H-
[1,2,4]triazole-3-thiol 5
The product was obtained from 4-amino-3-methyl-4H-
[1,2,4]triazole-5-thiol (1 g, 7.6 mmol) and 2,6-difluoro-benzalde-
hyde (1.09 g, 8.3 mmol) as white crystalline solid (0.94 g, 94%).
mp: 225–228uC. IR nmax (KBr): 1625 (s), 1285 (m), 892 cm
21. 1H
NMR (CDCl3 400 MHz) d: 13.8 (s, 1H, S-H), 10.6 (s, 1H,
CH=N-), 7.65–7.74 (m, 2H, Ar-H), 7.27–7.33(t, 1H, Ar-H), 2.32
(s, 3H, CH3). Anal. (C11H9F2N3S) C, H, N.
4-[(2,6-Difluoro-benzylidene)-amino]-5-ethyl-4H-
[1,2,4]triazole-3-thiol 6
The compound was obtained from 4-amino-3-ethyl-4H-
[1,2,4]triazole-5-thiol (1 g, 6.9 mmol) and 2,6-difluoro-benzalde-
hyde (0.98 g, 6.76 mmol) as white powder (0.75 g, 75%) mp: 185–
187uC. IR nmax (KBr): 1615 (s), 1245 (m), 875 cm
21. 1H NMR
(CDCl3 400 MHz) d: 13.8 (s, 1H, S-H), 10.5 (s, 1H, CH=N-),
Figure 7. Effect of compound 8 on the invasion of LM8G7 cells. Cells (2.56104) were seeded in MatrigelTM-coated Boyden chambers and were
incubated for 24 h with DMEM (A) or a medium containing 0.5 mM of compound 8 (B) or 1 mM compound 8 (C); the photographs (1006) shows
the cell on the lower surface of the filter (invaded) stained with the Diff-Quick solution. (D) Inhibition rate of the compound 8 on LM8G7 invasion
was presented as described under ‘‘Experimental Procedures’’. Bars represent the mean 6 SD of three independent experiments. * P,0.05 versus
control. ** P,0.01 versus control.
doi:10.1371/journal.pone.0039444.g007
Sugar Mimetic VEGF Binding Molecule
PLOS ONE | www.plosone.org 7 August 2012 | Volume 7 | Issue 8 | e39444
7.65–7.74 (m, 2H, Ar-H), 7.23–7.34 (t, 1H, Ar-H), 1.23 (t, 3H,
-CH3), 2.68–2.76 (q, 2H, -CH2-). Anal. (C12H11F2N3S) C, H, N.
4-[(2,6-difluoro-benzylidene)-amino]-5-phenyl-4H-
[1,2,4]triazole-3-thiol 7
The product was obtained from 4-amino-3-phenyl-4H-
[1,2,4]triazole-5-thiol (1 g, 5.2 mmol) and 2,6-difluoro-benzalde-
hyde (0.74 g, 3.8 mmol) as crystalline solid. Weight: 0.875 g; yield
87%; mp: 195–200uC; IR nmax (KBr): 1612 (s), 1236 (m), 842;
1H
NMR (CDCl3 400 MHz) d: 14.35 (s, 1H, S-H), 10.2 (s, 1H,
CH=N-), 7.89–7.96 (dd, 2H, Ar-H), 7.66–7.76 (m, 1H, Ar-H),
7.46–7.56 (dd, 2H, Ar-H), 7.28–7.34 (t, 1H, Ar-H); Anal.
(C16H11F2N3S) C, H, N.
SPR assay
The gold-coated glass chip (TOYOBO, Osaka, Japan) by
immersing in ethanol solution, containing 0.1 mM of the photo-
affinity linker and 0.9 mM dummy linker for 12 h as reported
previously [26]. The chip was washed successively with ethanol,
water, and ethanol. Then the chip is air dried to obtain the photo
reactive chip. The compounds 1–9 were spotted on the chip
(10 mM), washed, and dried in vacuo, and then irradiated at
365 nm under a UV transmission filter (Sigma-Koki, Japan). The
compounds were immobilized onto the photo-reactive linker that
bound to the gold-surface of the glass chip was set into an SPR
imaging instrument (TOYOBO), and each growth factor (50 mg/
mL) was injected onto the array surface at 0.1 ml/min and
incubated for 10 min. The SPR image and signal data were
collected with an SPR analysis program (TOYOBO). The SPR
difference image was constructed by using the Scion Image
program (Scion, MD).
Molecular docking study
As a model for docking simulations, we chose the solution
structure of the 55-residue heparin-binding domain of VEGF165,
which has been solved using data from two-dimensional homonu-
clear and three-dimensional heteronuclear NMR spectroscopy
(PDB entry: 2vgh) [31]. We also considered the FGF-2 from the
crystal structure of a ternary FGF-FGFR-heparin complex that
reveals a dual role for heparin in FGFR binding and dimerization
[32]. Molecular docking was carried out using discovery studio
program (Accelrys, California, USA). To dock compound 8 with
VEGF165, a CDOCKER protocol was used, which is an imple-
mentation of the algorithm CDOCKER [33] that allows us to run a
refinement docking of any number of ligands with a single protein
receptor, which is a grid-based molecular docking method that
employs CHARMm. The receptor is held rigid while the ligands are
allowed to flex during the refinement. MOLECULAR docking was
done by specifying the ligand placement in the active site using a
binding site sphere.
Interaction Analysis
The interaction of VEGF165 with heparin in the presence of
compound 8 was examined using a BIAcore J system (BIAcore
AB, Uppsala, Sweden). The heparin-immobilized sensor chip was
prepared as reported earlier [34]. The interaction of compound
8 with the heparin binding domain of VEGF165 was analysed by
injecting the various concentrations of compound 8 and
VEGF165 (250 nM) onto the surface of the sensor chip in running
buffer, pH 7.4 (HBS-EP; BIAcore AB), containing 10 mM
HEPES, 0.15 M NaCl, 3 mM EDTA, and 0.005% (w/v) Tween
20. The flow rate was kept at a moderate speed (30 ml/min)
according to the manufacturer’s recommendations. Each mixture
of the VEGF165 and compound 8 was allowed to interact with
the heparin-immobilized sensor chip for 2 min allowing associa-
tion and dissociation.
Cell lines
LM8G7 (a gift from M. Miyasaka, Department of Pharmaceu-
tical Chemistry, Osaka University) [23], a highly metastatic
murine osteosarcoma cell line with the potential to invade the
liver, was cloned from LM8G5 cells [35] as described [28] and
cultured in Dulbecco’s Modified Eagle’s Medium (DMEM)
supplemented with 10% (v/v) fetal bovine serum (FBS) (Thermo
Trace, Melbourne, Australia), streptomycin (100 mg/mL), penicil-
lin (100 units/mL), 1006 non-essential amino acids, b-mercapto-
ethanol (50 mM), 1006sodium pyruvate, and L-glutamine (2 mM)
at 37uC in a humidified 5% CO2 atmosphere. The cells were
harvested after incubation with 0.1% trypsin/1 mM EDTA in
PBS for 5 min at 37uC followed by gentle flushing with a pipette,
and subcultured three times a week. Mouse normal vascular
Figure 8. Effect of the compound 8 against the metastatic
potential of LM8G7 cells. C3H/HeN mice were intravenously injected
with LM8G7 cells via tail. Some mice received an intravenous injection
of compound 8 (0.25, 0.5, or 1.0 mg/kg) on day 3, 5 and 10. After 4
weeks, the mice were sacrificed, the number of liver nodules was
counted macroscopically, and the liver weight was measured in the
control and compound 8-treated animals. Representative livers from
mice injected with LM8G7 cells treated with DMEM (A), compound 8
(0.5 mg/kg) (B), and heparin (5 mg/kg) (C) are shown. The average liver
weight of the mock and the compound 8 treated mice (D). Heparin
from porcine intestinal mucosa was used as a positive control. The
possible synergistic or additive effects of compound 8 and heparin
were investigated by subsequent administration of compound 8
(0.25 mg/kg) and heparin (2.5 mg/kg) as described above. Data
represent mean values 6 SD for three independent experiments and
each experiment was conducted with 6 mice per group. * P,0.05 versus
control. Mann-Whitney U test.
doi:10.1371/journal.pone.0039444.g008
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endothelial cells (UVR2) were maintained in DMEM supplement-
ed with 10% (v/v) FBS.
Proliferation assay
Two tumor cell lines such as LM8, LM8G7, and UVR2
endothelial were used to evaluate the anti-proliferative activity of
the compounds. UVR2 (16104 cells) or LM8 or LM8G7 cells
(56103 cells) were seeded in 96-well plate and incubated overnight
at 37uC. The tumor cells or endothelial cells stimulated with
VEGF (2 ng/ml) were treated with various concentrations of
compounds 1–9 for an additional 48 h. 5 mL of TetraColor One
reagent was added and incubated for an additional 2–4 h and the
absorbance at 450 nm (Bio-Rad) was measured. Further, the effect
of compound 8 on VEGF-mediated proliferation of UVR2
endothelial was measured. The results were expressed as a
percentage of viable cells relative to cells treated with DMSO.
The viability of the cells was expressed in percentage terms and
IC50 value was calculated.
Human umbilical vein endothelial cells (HUVEC) were
obtained from the American Type Culture Collection (ATCC).
All experiments were done using endothelial cells between
passages 3 and 8. HUVECs were maintained in endothelial cell
growth medium M200 (Invitrogen) high glucose supplemented
with 15% fetal bovine serum, endothelial cell growth supplements
(LSGS Medium, Cascade Biologics), and glutamine at 37uC with
5% CO2. All cells were maintained as sub confluent cultures and
split 1:3, 24 h before use. HUVECs were seeded on 6-well plates
at a density of approximately 16105 cells/well in M200 medium
supplement with LSGS (Low Serum Growth Supplement). The
next day cells were stimulated with 10 ng/mL of VEGF in the
absence or presence of 1 and 10 mM of compound 8. After
48 hrs, AB (Alamar Blue) was added directly into culture media at
a final concentration of 10% and the plate was returned to the
incubator. Optical density (OD) of the plate was measured at 540
and 630 nm with a standard spectrophotometer at 3–4 h after
adding AB. As a negative control, AB was added to medium
without cells.
Real-time proliferation assay
The cell proliferation assay was done using the Real-Time Cell
Electronic Sensing (RT-CES) system (ACEA Biosciences, San
Diego, CA). LM8G7 (56103 cells/well) cells were seeded in
ACEA’s 966 e-plateTM in a final volume of 150 ml [36].
Approximately 24 h after seeding, when in log growth phase,
the cells were incubated with 150 ml of DMEM containing various
concentrations of compound 8 (final concentration 2 to 50 mM)
or DMEM containing DMSO as control. The effects of
compound 8 on the proliferation of LM8G7 cells were
monitored dynamically every 10 min. A cell index (quantitative
measurement of cell proliferation) was plotted against time. The
IC50 values were calculated from concentration-response curves by
a non-linear regression analysis using the GraphPad Prism
(GraphPad Prism Software Inc., San Diego).
In vitro cell migration and invasion assays
The ability of LM8G7 and UVR2 cells to migrate and invade
was assessed using the BD BioCoatTM chamber with or without
Matrigel (BD Biosciences) in vitro. The single cell suspensions of
LM8G7 cells or UVR2 cells were prepared by detaching and
resuspending in serum-free DMEM. Before the cells were added,
the chambers were rehydrated for 2 h in an incubator at 37uC. In
the upper chamber (8 mm PET pores), LM8G7 (66104 cells/ml)
or UVR2 (16105 cells/ml) cells were added along with
compound 8 (0.5 or 1.0 mM) in 500 ml DMEM and the lower
chambers were filled with DMEM containing 10% fetal bovine
serum. The MatrigelTM invasion chambers were incubated for a
further 22 h at 37uC. After incubation for 24 h, the cells that had
migrated or invaded through the membrane alone or the Matrigel-
coated membrane remained bound to the underside of the
membranes. In some instances, VEGF (2 ng/ml) was added
exogenously to understand the effect of compound 8 on VEGF-
induced migration of UVR2 cells. These cells were stained with
Diff-Quik staining kit and counted in five random microscopic
fields/filter. The percent inhibition of the invasion or migration of
LM8G7 cells or UVR2 cells by compound 8 were calculated.
In vitro angiogenesis assay
MatrigelTM (ECM 625, Chemicon) was added to a 24-well plate
in a final volume of 100 mL and allowed to solidify at 37uC for
30 min. UVR2 cells (46105 cells) were seeded to the ECMatrixTM-
coated wells in the presence or absence of compound 8 (0.5 or
1 mM) along with 2 ng/ml VEGF of FGF-2. After 18 h of culture,
the reorganization of the sub-confluent monolayer of UVR2 cells
in 3-dimensional ECMatrixTM was monitored and photographed
under an Olympus FX380 microscope attached to a 3CCD
camera.
Liver metastasis assay
Nine-week-old female C3H/HeN mice were obtained from
Japan SLC (Hamamatsu, Japan) and kept in standard housing. All
the experiments were performed according to a protocol approved
by the local animal care and use committee of Hokkaido
University. C3H/HeN mice were intravenously injected with
16106 LM8G7 cells in 200 ml of DMEM via the tail on day 0.
Some mice received an intravenous injection of compound 8
(0.25, 0.5, or 1.0 mg/kg) suspended in 200 mL of DMEM, on day
3, 5 and 10 after the tumor cell injection. After 4 weeks, the mice
were sacrificed and the number of liver nodules was counted
macroscopically in the control and compound 8-treated animals.
Heparin (5 mg/kg) was used as a positive control. The synergetic
effects of compound 8 and heparin were investigated by
subsequent administration of compound 8 (0.25 or 0.5 mg/kg)
and heparin (2.5 or 5.0 mg/kg) as described above.
Ethics statement
All animal experiments were conducted in accordance with
protocols specifically approved for this study by the animal care
and use committee (IACUC) at Hokkaido University, designed to
minimize the numbers of mice used and to minimize any pain or
distress.
Statistical analysis
The statistical analysis was done using software Origin 8
(OriginLab). The Mann-Whitney U test was used to determine P-
values.
Supporting Information
Figure S1 Interactions of the compound 8 within the
heparin binding pocket of FGF-2 (PDB ID: 1FQ9). The
compound 8 carbons are shown in grey color. The heparin
binding domain of FGF-2 amino acids carbons are shown in pink
color.
(TIF)
Figure S2 Effect of Compound 8 on FGF-2-induced tube
formation. The UVR2 cells were seeded in 6-well plates pre-
coated with MatrigelTM (ECM 625, Chemicon) and allowed to
Sugar Mimetic VEGF Binding Molecule
PLOS ONE | www.plosone.org 9 August 2012 | Volume 7 | Issue 8 | e39444
solidify the presence or absence of compound 8 (0.5 or 1 mM) at
37uC for 30 min. along with 2 ng/ml FGF-2. After 18 h of
culture, the reorganization of the sub-confluent monolayer of
UVR2 cells in 3-dimensional ECMatrixTM was monitored and
photographed. The number of intact tubes were counted in five
randomly chosen regions and expressed as the percentage of the
control, and the results are expressed as mean 6 S.D. Inhibition
rates of compound 8 on the tube formation of UVR2 cells was
presented.
(TIF)
Acknowledgments
We thank Prof. M. Miyasaka for providing the LM8 and LM8G7 cells. We
also thank Prof. H. Osada, Dr. Y. Kondoh and Dr. S. Akiko for providing
the SPR imaging data. We wish to thank C. V. Kavitha, S. L. Gaonkar,
and S. Nanjundaswamy, University of Mysore, for their help in preparing
the small molecules. We would like to acknowledge Dr. Purushothaman
Anurag, University of Alabama at Birmingham, USA and Dr. Sengottu-
velan Murugan, Hokkaido University, Japan, for their fruitful discussion
during the preparation of this manuscript.
Author Contributions
Conceived and designed the experiments: B KS KNT HKB PJH KSR.
Performed the experiments: B KS KNT HKB KSR. Analyzed the data: B
KS KNT HKB PJH KSR. Contributed reagents/materials/analysis tools:
B KS HKB KSR. Wrote the paper: B KS KNT HKB PJH KSR.
References
1. Goss PE, Baker MA, Carver JP, Dennis JW (1995) Inhibitors of carbohydrate
processing: A new class of anticancer agents. Clin Cancer Res 1: 935–944.
2. Marks PA (2007) Discovery and development of SAHA as an anticancer agent.
Oncogene 26: 1351–1356.
3. Tiligada E, Miligkos V, Delitheos A (2002) Cross-talk between cellular stress, cell
cycle and anticancer agents: mechanistic aspects. Curr Med Chem Anticancer
Agents 2: 553–566.
4. Dawson MI, Xia Z, Jiang T, Ye M, Fontana JA, et al. (2008) Adamantyl-
substituted retinoid-derived molecules that interact with the orphan nuclear
receptor small heterodimer partner: effects of replacing the 1-adamantyl or
hydroxyl group on inhibition of cancer cell growth, induction of cancer cell
apoptosis, and inhibition of SRC homology 2 domain-containing protein
tyrosine phosphatase-2 activity. J Med Chem 51: 5650–5662.
5. Compain P, Martin OR (2001) Carbohydrate mimetics-based glycosyltransfer-
ase inhibitors. Bioorg Med Chem 9: 3077–3092.
6. Slee DH, Romano SJ, Yu J, Nguyen TN, John JK, et al. (2001) Development of
potent non-carbohydrate imidazole-based small molecule selectin inhibitors with
antiinflammatory activity. J Med Chem 44: 2094–2107.
7. Perion R, Ferrieres V, Garcia-Moreno MI, Mellet CO, Duval R, et al. (2005)
1,2,3-Triazoles and related glycoconjugates as new glycoside inhibitors.
Tetrahedron 61: 9118–9128.
8. Gallos JK, Koumbis AE (2003) 1,3-Dipolar cycloadditions in the synthesis of
carbohydrate mimics. Part 1: Nitrile oxides and nitronates. Current Org Chem
7: 397–426.
9. Vlodavsky I, Bar-Shavit R, Ishai-Michaeli R, Bashkin P, Fuks Z (1991)
Extracellular sequestration and release of fibroblast growth factor: a regulatory
mechanism? Trends Biochem Sci 16: 268–271.
10. Hori A, Sasada R, Matsutani E, Naito K, Sakura Y, et al. (1991) Suppression of
solid tumor growth by immunoneutralizing monoclonal antibody against human
basic fibroblast growth factor. Cancer Res 51: 6180–6184.
11. Stein CA (1993) Suramin: a novel antineoplastic agent with multiple potential
mechanisms of action. Cancer Res 53: 2239–2248.
12. Wellstein A, Zugmaier G, Califano JA III, Kern F, Paik S, et al. (1991) Tumor
growth dependent on Kaposi’s sarcoma-derived fibroblast growth factor
inhibited by pentosan polysulfate. J Natl Cancer Inst 83: 716–720.
13. Benezra M, Vlodavsky I, Yayon A, Bar-Shavit R, Regan J, et al. (1992) Reversal
of basic fibroblast growth factor-mediated autocrine cell transformation by
aromatic anionic compounds. Cancer Res 52: 5656–5662.
14. Ciomei M, Pastori W, Mariani M, Sola F, Grandi M, et al. (1994) New
sulfonated distamycin A derivatives with bFGF complexing activity. Biochem
Pharmacol 47: 295–302.
15. Sola F, Farao M, Pesenti E, Marsiglio A, Mongelli N, et al. (1995) Antitumor
activity of FCE 26644 a new growth-factor complexing molecule. Cancer
Chemother Pharmacol 36: 217–222.
16. Jarvis A, Allerston CK, Jia H, Herzog B, Garza-Garcia A, et al. (2010) Small
molecule inhibitors of the neuropilin-1 vascular endothelial growth factor A
(VEGF-A) interaction. J Med Chem 53: 2215–2226.
17. Folkman J, Klagsbrun M (1987) Angiogenic factors. Science 235: 442–447.
18. Liotta LA, Steeg PS, Stetler-Stevenson WG (1991) Cancer metastasis and
angiogenesis: an imbalance of positive and negative regulation. Cell 64: 327–
336.
19. Cross M, Dexter TM (1991) Growth factors in development, transformation,
and tumorigenesis. Cell 64: 271–280.
20. Roskoski R Jr. (2007) VEGF signaling in tumor progression. Crit Rev Oncol
Hematol 62: 179–213.
21. Ishida K, Wierzba MK, Teruya T, Simizu S, Osada H (2004) Novel heparan
sulfate mimetic compounds as antitumor agents. Chem Biol 11: 367–377.
22. Kavitha CV, Lakshmi S, Basappa (2006) Synthesis and molecular structure
analysis of venlafaxine intermediate and its analog. J Chem Cryst 35: 957–963.
23. Basappa, Murugan S, Kavitha CV, Purushothaman A, Nevin KG, et al. (2010)
A small oxazine compound as an anti-tumor agent: a novel pyranoside mimetic
that binds to VEGF, HB-EGF, and TNF-a. Cancer letters 297: 231–243.
24. Gaonkar SL, Lokanatha Rai KM, Shetty SN (2008) Microwave-assisted
synthesis and evaluation of anti-inflammatory activity of new series N-substituted
2-butyl-5-chloro-3H-imidazole-4-carbaldehyde derivatives. Med Chem Res 18:
221–230.
25. Priya BS, Basappa, Swamy SN, Rangappa KS (2005) Synthesis and
characterization of novel 6-fluoro-4-piperidinyl-1,2-benzisoxazole amides and
6-fluoro-chroman-2-carboxamides: antimicrobial studies. Bioorg Med Chem 13:
2623–2628.
26. Saito A, Kawai K, Takayama H, Sudo T, Osada H (2008) Improvement of
photoaffinity SPR imaging platform and determination of the binding site of
p62/SQSTM1 to p38 MAP kinase. Chem Asian J 3: 1607–1612.
27. Basappa, Murugan S, Sugahara KN, Lee CM, ten Dam GB, et al. (2009)
Involvement of chondroitin sulfate E in the liver tumor focal formation of
murine osteosarcoma cells. Glycobiology 19: 735–742.
28. Asai T, Ueda T, Itoh K, Yoshioka K, Aoki Y, et al. (1998) Establishment and
characterization of a murine osteosarcoma cell line (LM8) with high metastatic
potential to the lung. Int J Cancer 76: 418–422.
29. Folkman J, Klagsbrun M (1987) Vascular physiology. A family of angiogenic
peptides. Nature 329: 671–672.
30. Basappa, Kavitha CV, Rangappa KS (2004) Simple and an efficient method for
the synthesis of 1-[2-dimethylamino-1-(4-methoxy-phenyl)-ethyl]-cyclohexanol
hydrochloride: (+/2) venlafaxine racemic mixtures. Bioorg Med Chem Lett 14:
3279–3281.
31. Fairbrother WJ, Champe MA, Christinger HW, Keyt BA, Starovasnik MA
(1998) Solution structure of the heparin-binding domain of vascular endothelial
growth factor. Structure 6: 637–648.
32. Schlessinger J, Plotnikov AN, Ibrahimi OA, Eliseenkova AV, Yeh BK, et al,
(2000) Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual
role for heparin in FGFR binding and dimerization. Mol Cell 6, 743–50.
33. Wu G, Robertson DH, Brooks CL III, Vieth M (2003) Detailed analysis of grid-
based molecular docking: A case study of CDOCKER-A CHARMm-based MD
docking algorithm. J Comput Chem 24: 1549–1562.
34. Bao X, Mikami T, Yamada S, Faissner A, Muramatsu T, et al. (2005) Heparin-
binding growth factor, pleiotrophin, mediates neuritogenic activity of embryonic
pig brain-derived chondroitin sulfate/dermatan sulfate hybrid chains. The
Journal of biological chemistry 280: 9180–9191.
35. Lee CM, Tanaka T, Murai T, Kondo M, Kimura J, et al. (2002) Novel
chondroitin sulfate-binding cationic liposomes loaded with cisplatin efficiently
suppress the local growth and liver metastasis of tumor cells in vivo. Cancer Res
62: 4282–4288.
36. Xing JZ, Zhu L, Jackson JA, Gabos S, Sun XJ, et al. (2005) Dynamic monitoring
of cytotoxicity on microelectronic sensors. Chem Res Toxicol 18: 154–161.
Sugar Mimetic VEGF Binding Molecule
PLOS ONE | www.plosone.org 10 August 2012 | Volume 7 | Issue 8 | e39444
